Correlation between intestinal microbes and the efficacy of bevacizumab / PD-1 monoclonal antibody therapy in patients with colorectal cancer

intestinal microbes regulate the efficacy of bevacizumab / PD-1 monoclonal antibody therapy in patients with colorectal cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900028063

Enrollment

Unknown

Registered

2019-12-09

Start date

2019-12-15

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Case series:bevacizumab / PD-1 monoclonal antibody treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with advanced colorectal cancer maintained by first-line treatment

Exclusion criteria

Exclusion criteria: Patients using antibiotics within one month

Design outcomes

Primary

Measure	Time frame
16S sequencing;	—

Contacts

Public ContactYaohui Gao

Shanghai Tenth People's Hospital

gaoyaohui187@163.com+86 15921324280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026